0001213900-21-059378 10-Q 56 20210930 20211115 20211115 CYREN Ltd. 0001084577 7372 000000000 L3 1231 10-Q 34 000-26495 211410858 10 HA-MENOFIM STREET 5TH FLOOR HERZLIYA L3 4672561 011-972-9-863-6888 10 HA-MENOFIM STREET 5TH FLOOR HERZLIYA L3 4672561 COMMTOUCH SOFTWARE LTD 19990419 10-Q 1 f10q0921_cyrenltd.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-26495 CYREN LTD. (Exact name of Registrant as specified in its charter) Israel Not applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 10 Ha-Menofim St., 5th Floor Herzliya, Israel 4672561 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code 011–972–9–863–6888 Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange on Title of Each Class Trading Symbol(s) Which Registered Ordinary Shares, par CYRN Nasdaq Capital Market value ILS 0.15 per share Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ? No ? Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ? No ? Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ? Accelerated filer ? Non-Accelerated filer ? Smaller reporting company ? Emerging growth company ? If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ? Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ? No ? Indicate the number of shares outstanding of each issuer’s classes of common stock, as of the latest practicable date: 90,363,745 ordinary shares as of October 31, 2021. Table of Contents Page PART I – FINANCIAL INFORMATION Item 1. Financial Statements Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020 2 Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2021 and 2020 4 Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2021 and 2020 5 Consolidated Statement of Changes in Shareholders’ Equity (unaudited) for the three and nine months ended September 30, 2021 and 2020 6 Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2021 and 2020 8 Notes to Consolidated Financial Statements (unaudited) 10 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3. Quantitative and Qualitative Disclosures About Market Risk 34 Item 4. Controls and Procedures 37 PART II – OTHER INFORMATION Item 6. Exhibits 38 SIGNATURES 39 i CYREN LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 ($USD in thousands, except share and per share amounts) (Unaudited) Page PART I – FINANCIAL INFORMATION ITEM 1. Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statement of Changes in Shareholders’ Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 -1- PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS. CYREN LTD. CONDENSED CONSOLIDATED BALANCE SHEETS ($USD in thousands, except share and per share amounts) September 30, December 31, 2021 2020 Unaudited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 17,932 $ 9,296 Trade receivables (net of allowances for credit losses of $77 and $201, as of September 30, 2021 and December 31, 2020, respectively) 3,824 960 Deferred commissions 932 980 Prepaid expenses and other receivables 1,653 779 Total current assets 24,341 12,015 LONG-TERM ASSETS: Long-term deferred commissions 939 1,125 Long-term lease deposits and prepaids 780 937 Operating lease right-of-use assets 9,431 10,900 Severance pay fund 880 745 Property and equipment, net 2,728 3,948 Intangible assets, net 5,753 7,797 Goodwill 20,689 21,476 Total long-term assets 41,200 46,928 Total assets $ 65,541 $ 58,943 The accompanying notes are an integral part of the interim condensed consolidated financial statements. -2- CYREN LTD. CONDENSED CONSOLIDATED BALANCE SHEETS ($USD in thousands, except share and per share amounts) September 30, December 31, 2021 2020 Unaudited LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES: Trade payables $ 903 $ 799 Convertible notes (related party) 10,000 10,000 Employees and payroll accruals 3,943 3,813 Accrued expenses and other liabilities ($176 and $37 attributable to related parties, respectively) 1,362 1,420 Operating lease liabilities 1,638 1,983 Deferred revenues 7,429 6,934 Total current liabilities 25,275 24,949 LONG-TERM LIABILITIES: Deferred revenues 538 644 Convertible Debentures ($237 and $234 attributable to related parties, respectively) 8,541 9,248 Long-term operating lease liabilities 8,574 9,866 Deferred tax liability 425 655 Accrued severance pay 924 838 Other liabilities 497 706 Total long-term liabilities 19,499 21,957 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS’ EQUITY: Ordinary shares nominal value ILS 0.15 par value - Authorized: 160,000,000 shares at September 30, 2021 (Unaudited) and 110,000,000 shares at December 31, 2020; Issued and Outstanding: 90,363,745 and 61,271,910 shares at September 30, 2021 (Unaudited) and December 31, 2020, respectively 3,745 2,392 Additional paid-in capital 282,749 258,962 Accumulated other comprehensive loss (1,563 ) (725 ) Accumulated deficit (264,164 ) (248,592 ) Total shareholders’ equity 20,767 12,037 Total liabilities and shareholders’ equity $ 65,541 $ 58,943 The accompanying notes are an integral part of the interim condensed consolidated financial statements. -3- CYREN LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ($USD in thousands, except share and per share amounts) (Unaudited) Three months ended Nine months ended September 30, September 30, 2021 2020 2021 2020 Unaudited Unaudited Revenues (1) $ 7,461 $ 9,114 $ 23,827 $ 27,944 Cost of revenues 3,732 3,792 11,332 11,168 Gross profit 3,729 5,322 12,495 16,776 Operating expenses: Research and development, net 4,100 4,769 12,460 12,264 Sales and marketing 2,785 2,942 8,154 9,123 General and administrative 2,336 2,302 6,801 6,992 Total operating expenses 9,221 10,013 27,415 28,379 Operating loss (5,492 ) (4,691 ) (14,920 ) (11,603 ) Other income (expense), net 5 1 (12 ) 9 Financial expenses, net (1) (320 ) (235 ) (821 ) (757 ) Loss before taxes on income (5,807 ) (4,925 ) (15,753 ) (12,351 ) Tax benefit 20 33 181 94 Net loss $ (5,787 ) $ (4,892 ) $ (15,572 ) $ (12,257 ) Basic and diluted net loss per share $ (0.07 ) $ (0.08 ) $ (0.21 ) $ (0.20 ) Weighted-average number of shares used in computing basic and diluted net loss per share 77,990 60,580 74,016 60,103 (1) Transactions with related parties are included in the line item above (refer to Footnote 8, Related Parties, of the Notes to Consolidated Financial Statements for additional information). The accompanying notes are an integral part of the interim condensed consolidated financial statements. -4- CYREN LTD. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS ($USD in thousands, except share and per share amounts) (Unaudited) Three months ended Nine months ended September 30, September 30, 2021 2020 2021 2020 Unaudited Unaudited Net loss $ (5,787 ) $ (4,892 ) $ (15,572 ) $ (12,257 ) Other comprehensive income (loss): Foreign currency translation adjustments (351 ) 591 (838 ) 590 Comprehensive loss $ (6,138 ) $ (4,301 ) $ (16,410 ) $ (11,667 ) The accompanying notes are an integral part of the interim condensed consolidated financial statements. -5- CYREN LTD. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY ($USD in thousands, except share amounts) (Unaudited) Three months ended September 30, 2020 Accumulated Number of other outstanding Additional comprehensive Total ordinary Share paid-in income Accumulated shareholders’ shares capital capital (loss) (*) deficit equity Balance as of June 30, 2020 (Unaudited) 60,197,223 $ 2,345 $ 257,045 $ (2,011 ) $ (238,694 ) $ 18,685 Restricted stock units vested 225,000 10 (10 ) - - - Payment of interest in shares 280,946 12 276 - - 288 Stock-based compensation related to employees, directors and consultants - - 724 - - 724 Issuance of shares upon early conversion of Convertible Debentures 216,334 9 142 151 Other comprehensive loss - - - 591 - 591 Net loss - - - - (4,892 ) (4,892 ) Balance as of September 30, 2020 (Unaudited) 60,919,503 $ 2,376 $ 258,177 $ (1,420 ) $ (243,586 ) $ 15,547 Nine months ended September 30, 2020 Accumulated Number of other outstanding Additional comprehensive Total ordinary Share paid-in income Accumulated shareholders’ shares capital capital (loss) (*) deficit equity Balance as of December 31, ) ) 2019 59,372,173 $ 2,309 $ 255,741 $ (2,010 $ (231,329 $ 24,711 Restricted stock units vested 856,132 38 (38 ) - - - Payment of interest in shares 410,322 17 414 - - 431 Stock-based compensation related to employees, directors and consultants - - 1,876 - - 1,876 Issuance of shares upon early conversion of Convertible Debentures 280,876 12 184 - - 196 Other comprehensive loss - - - 590 - 590 Net loss - - - - (12,257 ) (12,257 ) Balance as of September 30, 2020 (Unaudited) 60,919,503 $ 2,376 $ 258,177 $ (1,420 ) $ (243,586 ) $ 15,547 -6- CYREN LTD. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY ($USD in thousands, except share amounts) (Unaudited) Three months ended September 30, 2021 Accumulated Number of other outstanding Additional comprehensive Total ordinary Share paid-in income Accumulated shareholders’ shares capital capital (loss) (*) deficit equity Balance as of June 30, 2021 (Unaudited) 75,640,204 $ 3,056 $ 273,151 $ (1,212 ) $ (258,377 ) $ 16,618 Stock and warrant issuance for financing, net of costs (***) 14,152,779 662 8,614 - - 9,276 Restricted stock units vested 236,250 11 (11 ) - - - Payment of interest in shares 334,512 16 243 - - 259 Stock-based compensation related to employees, directors and consultants - - 752 - - 752 Other comprehensive loss - - - (351 ) - (351 ) Net loss - - - - (5,787 ) (5,787 ) Balance as of September 30, 2021 (Unaudited) 90,363,745 $ 3,745 $ 282,749 $ (1,563 ) $ (264,164 ) $ 20,767 Nine months ended September 30, 2021 Accumulated Number of other outstanding Additional comprehensive Total ordinary Share paid-in income Accumulated shareholders’ shares capital capital (loss) (*) deficit equity Balance as of December 31, 2020 61,271,910 $ 2,392 $ 258,962 $ (725 ) $ (248,592 ) $ 12,037 Stock issuance for financing, net of costs (**) 12,000,000 556 12,032 - - 12,588 Stock and warrant issuance for financing, net of costs (***) 14,152,779 662 8,614 - - 9,276 Restricted stock units vested 878,250 41 (41 ) - - - Payment of interest in shares 859,334 39 621 - - 660 Stock-based compensation related to employees, directors and consultants - - 1,757 - - 1,757 Issuance of shares upon early conversion of Convertible Debentures 1,201,472 55 804 - - 859 Other comprehensive loss - - - (838 ) - (838 ) Net loss - - - - (15,572 ) (15,572 ) Balance as of September 30, 2021 (Unaudited) 90,363,745 $ 3,745 $ 282,749 $ (1,563 ) $ (264,164 ) $ 20,767 (*) Relates to foreign currency translation adjustments. (**) Net of issuance costs of $1,212. (***) Net of issuance costs of $914 The accompanying notes are an integral part of the interim condensed consolidated financial statements. -7- CYREN LTD. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS ($USD in thousands, except share and per share amounts) (Unaudited) Nine months ended September 30, 2021 2020 Unaudited Cash flows from operating activities: Net Loss $ (15,572 ) $ (12,257 ) Adjustments to reconcile net loss to net cash used in operating activities: Loss on disposal of property and equipment 17 12 Depreciation 1,630 1,809 Stock-based compensation 1,757 1,876 Amortization of intangible assets 2,230 2,071 Amortization of deferred commissions 1,010 1,181 Amortization of operating lease right-of-use assets 1,269 1,508 Interest on convertible notes 430 436 Interest and amortization of debt issuance costs on Convertible Debentures 523 400 Deferred taxes, net (208 ) (171 ) Changes in assets and liabilities: Trade receivables (2,900 ) (126 ) Prepaid expenses and other receivables (711 ) (456 ) Deferred commissions (773 ) (900 ) Change in long-term lease deposits and prepaids (13 ) (89 ) Trade payables 85 (289 ) Employees and payroll accruals, accrued expenses and other liabilities 127 (90 ) Deferred revenues 527 1,034 Accrued severance pay, net (48 ) (36 ) Operating lease liabilities (1,452 ) (1,545 ) Other long-term liabilities (390 ) 184 Net cash used in operating activities (12,462 ) (5,448 ) Cash flows from investing activities: Proceeds from sale of property and equipment 6 6 Capitalization of technology (262 ) (1,100 ) Purchase of property and equipment (466 ) (1,543 ) Net cash used in investing activities (722 ) (2,637 ) The accompanying notes are an integral part of the interim consolidated financial statements. -8- CYREN LTD. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS ($USD in thousands, except share and per share amounts) (Unaudited) Nine months ended September 30, 2021 2020 Unaudited Cash flows from financing activities: Proceeds from Convertible Debentures, net of debt issuance costs - 9,442 Proceeds from stock and warrant issuance, net of costs 9,276 - Proceeds from stock issuance, net of costs 12,588 - Net cash provided by financing activities 21,864 9,442 Effect of exchange rate changes on cash, cash equivalents and restricted cash (36 ) (14 ) Increase in cash, cash equivalents and restricted cash 8,644 1,343 Cash, cash equivalents and restricted cash at the beginning of the period 9,914 12,127 Cash, cash equivalents and restricted cash at the end of the period $ 18,558 $ 13,470 Supplemental cash flow disclosures: Cash paid during the year for: Interest $ 143 $ 144 Supplemental disclosure of non-cash transactions: Purchase of property and equipment by credit $ (25 ) $ (214 ) Operating lease right-of-use asset exchanged for lease obligations - 3,772 Issuance of shares on early conversion of Convertible Debentures 859 196 Issuance of shares for payment of interest on convertible notes 143 144 Issuance of shares for payment on Convertible Debentures 518 287 Net change in accrued payroll expenses related to capitalization of technology - (26 ) Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow: Cash and cash equivalents $ 17,932 $ 12,894 Restricted cash included in long-term restricted lease deposits 626 576 Total cash, cash equivalents and restricted cash $ 18,558 $ 13,470 The accompanying notes are an integral part of the interim consolidated financial statements. -9- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 1:- GENERAL Cyren Ltd. (henceforth “Cyren”) was incorporated under the laws of the State of Israel on February 10, 1991 and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999 under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated will be referred to in these consolidated financial statements as the “Company”. The Company is engaged in developing and marketing cyber security solutions to identify and protect customers from threats in email, files, and the web. The Company sells its cloud-based solutions worldwide, in a Software-as-a-Service model, to enterprises as well to OEMs (Original Equipment Manufacturers) which include leading email providers, other cybersecurity vendors and managed services providers (MSPs). The Company operates in one reportable segment, which constitutes its reporting unit. NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES a. Interim Financial Statements The accompanying condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, and the condensed statement of changes in shareholders’ equity for the three and nine months ended September 30, 2021 and 2020, as well as the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of September 30, 2021, as well as its results of operations for the three and nine months ended September 30, 2021 and 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ended December 31, 2021 or for other interim periods or for future years. b. Over the past several years, the Company has made significant investment in product development, as well as sales & marketing. The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. At September 30, 2021, the Company’s cash and cash equivalents position is not sufficient to fund the Company’s planned operations for at least one year beyond the date of the filing date of the condensed consolidated financial statements. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand, reducing operating spend, potentially divesting non-core assets, amending certain existing debt securities and issuing equity and/or debt securities. On February 11, 2021, the Company entered into securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12,000,000 of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12,588. On September 15, 2021, the Company entered into securities purchase agreements with several institutional investors to raise approximately $10,190 through the issuance of 14,152,779 of the Company’s ordinary shares and warrants to purchase up to 14,152,779 ordinary shares, at a purchase price of $0.72 per share and associated warrant, in a private placement priced "at-the-market" under Nasdaq Rules for net proceeds of $9,276. The current cash balance and historical trend of cash used in operations along with the maturity of the convertible notes in December 2021, and lack of certainty regarding a future capital raise and our ability to renegotiate the terms of the convertible notes, raises substantial doubt about our ability to continue as a going concern for the next twelve months from the date of issuance of these financial statements. We anticipate that we will have sufficient funds to pay the principal of the convertible notes on their maturity date. While the Company has successful raised funds in the past, there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms, would have serious consequences on our financial condition and results of operations. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The condensed consolidated financial statements for the three and nine months ended September 30, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. -10- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.) c. Significant accounting policies The accompanying unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2021. Other than the change described below, there have been no changes to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that have had a material impact on the unaudited interim consolidated financial statements and related notes. d. Use of estimates: The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to fair value and useful lives of intangible assets, fair value of earn-out liabilities, valuation allowance on deferred tax assets, income tax uncertainties, fair values of stock-based awards, other contingent liabilities and estimates used in applying the revenue recognition policy. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. e. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. U.S. GAAP requires an evaluation of whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued. Initially, this evaluation does not consider the potential mitigating effect of management’s plans that have not been fully implemented. When substantial doubt exists, management evaluates the mitigating effect of its plans if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued or prior to the conditions or events that create the going concern risk. The condensed consolidated financial statements as of September 30, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. -11- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.) f. Basic and diluted net loss per share: Basic net loss per share has been computed using the weighted-average number of ordinary shares outstanding during the period. Diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each period, plus the weighted average number of dilutive potential ordinary shares considered outstanding during the period. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. In periods where the Company reports a net loss, the effect of anti-dilutive stock options, restricted stock units, convertible notes, Convertible Debentures, and warrants are excluded and diluted net loss per share is equal to basic net loss per share. For the three months period ended September 30, 2021 and September 30, 2020, 26,877,551 and 24,093,385 ordinary shares were excluded from the calculation of diluted net EPS due to their anti-dilutive effect, respectively. For the nine months period ended September 30, 2021 and September 30, 2020, 42,098,143 and 74,627,734 ordinary shares were excluded from the calculation of diluted net EPS due to their anti-dilutive effect, respectively. g. Recently issued and adopted pronouncements: In December 2019, the FASB issued ASU No. 2019-12, “Simplifying the Accounting for Income Taxes” under ASC 740, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. The Company adopted this new guidance in the first quarter of fiscal 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements. h. New accounting pronouncements not yet adopted: In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements. -12- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 3:- LEASES The Company adopted ASC 842, Leases, the new standard as of January 1, 2019, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a full retrospective approach. The Company has elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard which does not require it to reassess the prior conclusions about lease identification, lease classification, and initial direct costs. In addition, the Company has elected the short-term lease exception for leases with a term of 12 months or less. As part of this election, it will not recognize right-of-use assets and lease liabilities on the balance sheet with terms less than 12 months. The Company also elected the practical expedient to not separate lease and non-lease components for all our leases. This will result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability being greater than if the policy election was not applied. Some leases include one or more options to extend the lease. The exercise of options to extend the lease is typically at the Company’s sole discretion; therefore, the majority of renewals to extend the lease terms are included in our right of use assets and lease liabilities as they are reasonably certain of exercise. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. Lease modifications result in the remeasurement of the lease liability. The right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate based on the information available at the date of adoption in determining the present value of the lease payments. Some of the real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease adoption. Additional payments based on the change in an index or rate are recorded as a period expense when incurred. The Company has various operating leases for office space and vehicles that expire through 2030. Below is a summary of our operating right-of-use assets and operating lease liabilities as of September 30, 2021: Operating lease right-of-use assets $ 9,431 Operating lease liabilities, current $ 1,638 Operating lease liabilities long-term 8,574 Total operating lease liabilities $ 10,212 -13- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 3:- LEASES (Cont.) Minimum lease payments for our right of use assets over the remaining lease periods as of September 30, 2021, are as follows: Year ended December 31, 2021 $ 595 2022 1,827 2023 1,632 2024 1,629 2025 1,626 Thereafter 4,439 Total undiscounted lease payments $ 11,748 Less: Interest 1,536 Present value of lease liabilities $ 10,212 Premises rent expense was $679 and $714 for the three months ended September 30, 2021 and 2020, respectively, and $2,100 for the nine months ended September 30, 2021 and 2020. As of September 30, 2021, the Company subleases two real estate properties. Sublease receipts were $167 and $171 for the three months ended September 30, 2021 and 2020, respectively, and $496 and $361 for the nine months ended September 30, 2021 and 2020, respectively. The Company has elected the practical expedient to not separate lease components from non-lease components. The weighted-average remaining lease terms and discount rates for all operating leases were as follows as of September 30, 2021: Remaining lease term and discount rate: Weighted-average remaining lease term (years) 6.7 Weighted-average discount rate 4.35 % -14- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 4:- COMMITMENTS AND CONTINGENCIES a. Cyren Ltd., which was incorporated in Israel, partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (“IIA”) for the support of certain research and development activities conducted in Israel. In connection with specific research and development, the Company received $3,699 of participation payments from the IIA through 2018 and none since 2018. In return for the IIA’s participation in this program, the Company is committed to paying royalties at a rate of 3% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at annual LIBOR rate. The Company’s total commitment for royalties payable with respect to future sales, based on IIA participations received, net of royalties paid or accrued, totaled $2,610 and $2,713 as of September 30, 2021 and December 31, 2020, respectively. For the three months ended, September 30, 2021 and 2020, $31 and $64, respectively, were recorded as cost of revenues with respect to royalties due to the IIA. For the nine months ended, September 30, 2021 and 2020, $90 and $173, respectively, were recorded as cost of revenues with respect to royalties due to the IIA. b. Litigation: On June 28, 2017 a vendor filed a Statement of Claim in the Tel Aviv District Court (the “SOC”). According to the vendor’s SOC, the Company entered into an agreement with the vendor for receipt of services, based on a database developed by the vendor. In September 2015, the Company terminated the agreement with the vendor, effective as of December 31, 2015. The vendor claimed that the Company had continued to make use of the vendor’s database post termination thus breaching the agreement, infringing on the vendor’s rights and commercial secrets, and being unjustly enriched. The vendor claimed damages of approximately $3,150 and injunctive relief ordering the Company and/or its customers to delete any remaining data and to cease from utilizing such data. The Company denied all claims and filed a Statement of Defense on November 15, 2017. Pretrial was scheduled for May 15, 2018. In accordance with the court’s recommendation from November 28, 2017, the parties agreed to examine a non-binding mediation process and appointed a mediator. The parties agreed to conduct a third-party audit of the Company’s databases in the scope of the mediation. In September 2018 and January 2019, the same vendor filed a lawsuit against two of the Company’s customers in the United States. The vendor alleged that the clients misappropriated the vendor’s trade secrets and sought injunctive relief and monetary damages in an amount to be determined. Both customers contended that the allegations related to the services they receive from the Company, and the Company agreed to indemnify both clients against these claims. On September 30, 2019, the court dismissed one of the lawsuits in its entirety for lack of personal jurisdiction and, in the second lawsuit, dismissed part of the claims with prejudice but granted the vendor the right to amend its other claims. On October 31, 2019, the vendor filed an amended complaint. In December 2019, the Company reached a settlement with the vendor and the Company agreed to pay $750; $375 in December 2019 and the remaining portion in January 2020. As of March 31, 2021, the Company has paid all amounts due under this settlement. -15- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 5:- ShareHOLDERS’ EQUITY a. General: Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends if declared. On July 8, 2021, the shareholders of the Company approved an increase in the number of authorized ordinary shares from 110,000,000 ordinary shares of nominal value NIS 0.15 per share to 160,000,000 ordinary shares of nominal value NIS 0.15 per share. b. Issuance of convertible notes: On December 5, 2018 the Company issued $10,000 aggregate principal amount of convertible notes in a private offering. The notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes have a 3-year term and mature in December 2021, unless converted in accordance with their terms prior to maturity. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019, Cyren announced the closing of a rights offering that raised gross proceeds of $8,019. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. On February 16, 2021, Cyren announced securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12,000,000 of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12,588. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.38. On September 17, 2021, we issued to several institutional investors in a private placement 14,152,799 of our ordinary shares at a purchase price of $0.72 per share and warrants to purchase up to 14,152,779 ordinary shares at an exercise price of $0.60 per share. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.02. In addition, the notes would be subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price). The Company incurred interest expense for the three and nine months ended September 30, 2021 of $145 and $430, respectively. The Company incurred interest expense for the three and nine months ended September 30, 2020 of $153 and $436, respectively. In June 2021, the Company paid semi-annual interest payments totaling, $287, of which $143 was paid in cash and the remaining portion through the issuance of 233,400 shares. The Company has accrued interest of $176 as of September 30, 2021. As of September 30, 2021, the principal balance of the convertible notes is $10,000. As the convertible notes mature in December 2021, the Company is currently negotiating to restructure the convertible notes with the noteholders and at this time is uncertain as to the outcome. If the restructuring discussions are not successful, the Company intends to use its available cash resources to repay the principal upon maturity per the terms of the convertible notes. -16- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.) c. Issuance of Convertible Debentures : In March 2020, the Company entered into purchase agreements with a select group of accredited investors for the purchase of $10,250 aggregate principal amount of Convertible Debentures in a private placement. Upon the closing, the Company received approximately $9,400 (net of $800 in issuance expenses). The debentures are unsecured, subordinated obligations of Cyren and carry a 5.75% interest rate per annum, payable semi-annually in cash or ordinary shares at Cyren’s election. The debentures have a four-year term and mature in March 2024, unless converted in accordance with their terms prior to maturity. The debentures have a conversion price of $0.75 per share and are convertible into 1,333 ordinary shares per $1,000 principal amount of debentures. The conversion price is subject to adjustment based on the price and timing of future equity offerings and other customary adjustments. Upon the satisfaction of price and other conditions, Cyren has the right to force the conversion of the debentures. In March 2021, the Company paid semi-annual interest payments totaling, $259, which was paid through the issuance of 291,422 shares. In September 2021, the Company paid semi-annual interest payments totaling, $259, which was paid through the issuance of 334,512 shares. For the quarter ended March 31, 2021, two debenture holders converted $909 of principal plus interest of their debentures, which was a portion of their holding. The principal and interest were paid through the issuance of 1,201,472 shares. There were no conversions for the quarters ended June 30, 2021 or September 30, 2021. On June 11, 2020, one of the debenture holders converted $48 of principal plus interest of their debentures, which was a portion of their holding. The principal and interest was paid through the issuance of 64,542 shares. The Company incurred interest expense for the three and nine months ended September 30, 2021 of $180 and $523, of which $44 and $134 are related to the amortization of debt issuance costs, respectively. The Company incurred interest expense for the three and nine months ended September 30, 2020 of $188 and $400, of which $49 and $98 are related to the amortization of debt issuance costs, respectively. The Company has accrued interest of $20 as of September 30, 2021. The principal balance of the Convertible Debentures as of September 30, 2021 was $9,000. As of September 30, 2021, the total estimated fair value of the Convertible Debentures was approximately $5,600. The fair value was determined based on the closing trading price of $0.62 per share multiplied by the Convertible Debentures principal balance as of the last day of trading for the period The fair value of the Convertible Debentures is considered a Level 2 within the fair value hierarchy and was determined based on inputs that are observable in the market or that could be derived from, or corroborated with, observable market data, quoted price of the Convertible Debentures in an over-the-counter market. d. Equity Incentive Plan: On December 22, 2016, the Company’s shareholders approved a new equity plan - the 2016 Equity Incentive Plan (the “Equity Incentive Plan”). This plan, along with its respective Israeli appendix, replaced all then-existing employee and consultants stock option plans. -17- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.) The Equity Incentive Plan allows for the issuance of Restricted Stock Units (“RSUs”), as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon the termination of the optionee’s employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are cancelled or not exercised within the option term become available for future grant. On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the 2016 Equity Incentive Plan and its respective Israeli Appendix to a total of 11,200,000. As of September 30, 2021, an aggregate of 6,481,815 ordinary shares of the Company are still available for future grant under the Equity Incentive Plan. e. Non-Employee Directors stock option plan: In 1999, the Company adopted the 1999 Directors Stock Option Plan, and in 2008 shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, the Company’s shareholders approved a new equity plan - the 2016 Non-Employee Director Equity Incentive Plan (the “Non-Employee Director Plan”). This plan, along with its respective Israeli appendix, replaced all existing Directors stock option plans. The Non-Employee Director Plan allows for the issuance of Restricted Stock Units (“RSUs”), as well as options. Each option and RSU granted under the Non-Employee Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon the termination of the relationship with the Company. On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the Non-Employee Director Plan and its respective Israeli Appendix to a total of 1,150,000 Ordinary Shares. As of September 30, 2021, an aggregate of 698,050 ordinary shares of the Company are still available for future grant to non-employee directors. -18- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.) f. A summary of the Company’s employees and directors’ stock option activity under the plans is as follows: Weighted- average Weighted- remaining average contractual Aggregate Number of exercise term intrinsic options price (years) value Outstanding at December 31, 2020 6,205,860 $ 2.09 3.18 $ - Granted 230,000 0.75 Exercised - - Expired and forfeited (2,785,270 ) 2.16 Outstanding at September 30, 2021 3,650,590 $ 1.95 2.95 $ 2 Options vested and expected to vest at September 30, 2021 3,558,211 $ 1.96 2.92 $ 2 Exercisable options at September 30, 2021 2,536,407 $ 2.03 2.46 $ - Weighted-average fair value of options granted during the quarter $ 0.39 The aggregate intrinsic value in the tables above represents the total intrinsic value (the difference between the fair value of the Company’s ordinary shares as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period. The total intrinsic value of options exercised during the quarters ended September 30, 2021 and 2020 was $0, and $0, respectively. The weighted-average grant date fair value of options granted to employees and directors during the quarters ended September 30, 2021 and 2020, was $0.39 and $0.66, respectively. As of September 30, 2021, the Company had $750 of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted-average period of 1.73 years. g. The employee and director options outstanding as of September 30, 2021, have been separated into ranges of exercise prices, as follows: Outstanding Exercisable Weighted- average Weighted- Weighted- remaining average average contractual exercise exercise Options life in price per Options price per Exercise price per share outstanding years share exercisable share $0.54 - $1.64 989,162 3.23 $ 1.37 546,152 $ 1.52 $1.70 - $2.00 705,550 2.05 $ 1.89 621,346 $ 1.91 $2.05 - $2.14 1,133,640 3.51 $ 2.09 679,896 $ 2.09 $2.30 - $2.75 644,912 2.53 $ 2.39 552,705 $ 2.38 $2.90 - $3.20 177,326 2.90 $ 2.90 136,308 $ 2.96 3,650,590 2.95 $ 1.95 2,536,407 $ 2.03 -19- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.) h. Options to non-employees and non-directors: Exercise Options price per Options Exercisable Issuance date outstanding share exercisable through February 10, 2016 40,000 $ 1.44 40,000 Feb-22 January 24, 2017 25,000 $ 2.00 25,000 Jan-23 65,000 65,000 The options vest and become exercisable at a rate of 1/16 of the options every three months. As of September 30, 2021, the Company did not have any unrecognized compensation expense related to non-employee and non-director non-vested stock options. i. A summary of the Company’s RSUs activity for employees, directors, and non-employees under the plans is as follows: Weighted- average Number grant date of RSUs fair value Awarded and unvested at December 31, 2020 2,183,500 $ 1.50 Granted 5,233,400 0.83 Vested (878,250 ) 1.49 Forfeited (152,500 ) 1.29 Awarded and unvested at September 30, 2021 6,386,150 $ 0.96 As of September 30, 2021, the Company had approximately $5,225 of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted-average period of 2.62 years. -20- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.) j. The total stock-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine months ended September 30, 2021 and 2020 was as follows: Three months ended Nine months ended September 30, September 30, 2021 2020 2021 2020 Unaudited Unaudited Cost of revenues $ 83 $ 21 $ 187 $ 85 Research and development 55 70 150 229 Sales and marketing 100 65 228 204 General and administrative 514 568 1,192 1,358 $ 752 $ 724 $ 1,757 $ 1,876 NOTE 6:- SEGMENT AND GEOGRAPHIC INFORMATION Summary information about geographic areas: ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of professional services, maintenance, and technical support (see note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas: a. The following sets forth total revenue by geographic area based on the billing address of the customer: Three months ended Nine months ended September 30, September 30, 2021 2020 2021 2020 Unaudited Unaudited United States $ 3,200 $ 4,201 $ 10,413 $ 13,075 Germany 1,991 2,109 6,120 6,269 Europe 851 966 2,788 2,993 Asia Pacific 443 667 1,606 1,900 Israel 849 1,001 2,535 3,350 Other 127 170 365 357 $ 7,461 $ 9,114 $ 23,827 $ 27,944 -21- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 6:- SEGMENT AND GEOGRAPHIC INFORMATION (Cont.) b. Major customers: During the quarter ended September 30, 2021 and 2020, 17% and 22%, respectively, of the Company’s revenues were derived from a single customer. For the quarter ended September 30, 2021, no other customer accounted for more than 10% of total revenue. c. Remaining performance obligations: As of September 30, 2021, approximately $26,625 of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for non-cancellable contracts. The Company expects to recognize revenue on approximately 26% of these remaining performance obligations during the remainder of 2021, approximately 51% in 2022, with the remainder recognized thereafter. d. Revenue generated by Customer Type: Three months ended Nine months ended September 30, September 30, 2021 2020 2021 2020 Unaudited Unaudited OEM/Embedded Security (*) $ 5,876 $ 7,354 $ 18,940 $ 22,771 Enterprise/SMB (**) 1,585 1,760 4,887 5,173 $ 7,461 $ 9,114 $ 23,827 $ 27,944 (*) This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Feeds into their infrastructure and/or products to protect their customers and users. (**) In this market, Cyren provides enterprise customers email security products, threat intelligence, and cloud-based sandbox threat analysis to protect their employees, data and IP. e. The following sets forth the Company’s long-lived tangible assets, net by geographic area: September 30, December 31 2021 2020 Unaudited Israel $ 5,852 $ 6,490 United States 971 1,964 Germany 4,374 5,247 Other 962 1,147 $ 12,159 $ 14,848 -22- CYREN LTD. NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS ($USD in thousands, except share and per share amounts) (Unaudited) NOTE 7:- FINANCIAL EXPENSE, NET Three months ended Nine months ended September 30, September 30, 2021 2020 2021 2020 Unaudited Unaudited Expenses: Interest expense, net of interest capitalized $ (333 ) $ (410 ) $ (964 ) $ (902 ) Foreign currency exchange differences, net 29 190 194 196 Other (16 ) (15 ) (51 ) (51 ) $ (320 ) $ (235 ) $ (821 ) $ (757 ) NOTE 8:- RELATED PARTIES a. Balances with related parties: September 30, December 31, 2021 2020 Unaudited Interest expense accrual – Convertible Notes (*) $ 176 $ 32 Interest expense accrual – Convertible Debentures (**) 1 4 Short term Convertible Notes (***) 10,000 10,000 Long term Convertible Debentures (****) 237 234 (*) Related to the semi-annual interest payable due in June and December related to the convertible notes entered into December 5, 2018. See note 5b. for further details. (**) Related to the semi-annual interest payable due in September and March related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details. (***) Related to the convertible notes entered into December 5, 2018. See note 5b. for further details. (****) Related to the Convertible Debentures entered into March 19, 2020 See note 5c. for further details. b. Transactions with related parties: Three months ended Nine months ended September 30, September 30, 2021 2020 2021 2020 Unaudited Unaudited Revenue (*) $ 17 $ - $ 17 $ - Interest expense on Convertible Notes (**) $ 145 $ 153 $ 430 $ 436 Interest expense on Convertible Debentures (***) $ 5 $ 5 $ 15 $ 10 (*) Related to a new OEM customer agreement signed in Q3 2021 where Cyren and this customer share the same investor. (**) Related to the semi-annual interest payable due in June and December related to the convertible notes entered into December 5, 2018. See note 5b. for further details. (***) Related to the semi-annual interest payable due in September and March related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details. - - - - - - - - - - - - - -23- ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the information contained in our consolidated financial statements and the notes thereto. The following discussion and analysis includes forward-looking statements that involve certain risks and uncertainties, including, but not limited to, those described in Item 1A. Risk Factors in our most recent Annual Report on Form 10-K (the “2020 Annual Report”) and Item 1A. Risk Factors in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2021. Our actual results may differ materially from those discussed below. See “Special Note Regarding Forward-Looking Statements” below. Overview Purpose built for the cloud, Cyren was an early pioneer and leading innovator of cloud delivered Software-as-a-Service (SaaS) cybersecurity solutions that protect businesses, their employees and customers against threats from email, files, and the web. We believe our cloud-based approach to security sets us apart from other vendors in the market. Our security solutions are architected around the fundamental belief that cyber security is a race against time – and the cloud best enables the speed, sophistication, and advanced automation needed to detect and block threats as they emerge on the internet. As more and more businesses move their data and applications to the cloud, they need a security provider that is able to keep pace. Security threats are more prevalent and stealthier than ever. As cybercrime has become more sophisticated, every malware, phishing, and ransomware variant is unique, making it more difficult to detect attacks. While organizations have traditionally protected their users with gateway security appliances at their network perimeter, more frequent and evasive attacks combined with a more distributed workforce are reducing the effectiveness of this approach. Traditional appliances lack the real-time threat intelligence and processing power to detect emerging threats, and the growth of mobile devices and an increasingly distributed workforce means that more and more business is conducted outside of the traditional network perimeter. As a result, when new attacks appear in a matter of seconds, legacy cybersecurity products can leave companies vulnerable for hours, days, or even weeks. Cyren’s cloud security products and services fall into three categories: ? Cyren Threat Detection Services – these services detect a variety of threats in email, files, and from the web, and are embedded into products from the world’s leading email providers, cyber security vendors and managed service providers. Cyren Threat Detection Services include our Email Security Detection Engine, Malware Detection Engine, Web Security Engine, and Threat Analysis Service. ? Cyren Threat Intelligence Data – Cyren’s Threat Intelligence Products provide valuable threat intelligence data that can be used by enterprise or OEM customers to support threat detection, threat hunting, and incident response. Cyren’s Threat Intelligence offerings include IP Reputation Intelligence, Phishing Intelligence, Malware Intelligence, and Zombie Intelligence. ? Cyren Enterprise Email Security Products – these include cloud-based solutions designed for enterprise customers and are sold either directly or through channel partners. Cyren Enterprise Email Security products include Cyren Email Security, a cloud-based secure email gateway, and Cyren Inbox Security, an anti-phishing product for Microsoft 365. Key Opportunities and Challenges Threat Landscape The last several years have possibly experienced the greatest amount of dramatic global incidents directly related to malware and cyber threats since the advent of the internet. From election hacks to global ransomware attacks, malware threats are at an all-time high. Phishing attacks have become increasingly common, and no company, large or small seems immune to these threats. Hackers have become more successful at monetizing these attacks, and as long as these activities prove lucrative, we expect these incidents to continue. -24- Cloud and Mobility Businesses are going through a massive change in their IT strategies as they look to drive more business value, agility, and better customer experiences, while cloud and mobility are becoming increasingly important, as evidenced by the following trends: ? Business internet traffic continues to increase every year; ? Data and applications are increasingly moving to the cloud; ? More and more users are working remotely, particularly since the COVID-19 pandemic; ? Buyers continue to move away from traditional on-premise solutions; ? Mature and legacy on-premise deployments are reaching the end of life and are increasingly being replaced by cloud and SaaS alternatives; ? IT security staffing shortages; ? Increasingly fast, sophisticated, expensive, and high-profile attacks target organizations of all sizes; ? Compliance and regulatory mandates; ? Heightened cybercrime activity among commercial enterprises and nation-states; ? Automation is increasingly considered critical to accelerating detection and protection; and ? The need to simplify operations through vendor consolidation. These are some of the reasons why we believe Cyren’s vision for 100% cloud security is compelling to IT security teams looking to protect their businesses in today’s cloud-centric mobile-first world. Growing Our Enterprise Business Cyren has prioritized growing its enterprise revenues. With the mid-2020 release of our anti-phishing solution, Cyren Inbox Security (CIS), we believe helping enterprises mitigate phishing attacks is our most significant revenue growth opportunity. Given the substantial size of the enterprise anti-phishing market, Cyren believes this new revenue stream has the potential to grow faster than our legacy OEM business. As this CIS business grows, it will gradually contribute to a larger portion of our overall revenue, and as a result, we expect deferred revenue to increase and our operating results and cash flow to improve. Investments in Operations, Research and Development and Sales and Marketing Our cost of revenues, research and development expenses, and sales and marketing expenses are all significant contributing factors to our operating losses. Over time, we expect we will increase utilization of our cloud infrastructure which we expect will provide the opportunity for improved gross margins. Our investments in research and development are required in order to enhance and improve our solutions. In the future, we expect to lower the rate of R&D investment as a percentage of revenue. The return on our sales and marketing investment is tied to attracting new customers and enhancing our business with existing customers, thereby lowering the overall sales and marketing costs as a percent of revenues. During 2020 we reduced our overall headcount in order to reduce expenses, and we believe managing future headcount and expense growth will be key in improving our gross and operating margins over time. In the third quarter of 2021, headcount remained consistent with the second quarter of 2021. Headcount on a year-over-year basis is down by about 10% which has led to a decline in operating expenses on a year-to-date basis compared to the corresponding period a year ago. We continue to monitor expenses and where possible, reduce expenses. We believe managing future headcount and expense growth will be key in improving our gross and operating margins over time given the recent decline in revenue. Components of our Operating Results Revenue We derive revenues from the sale of real-time cloud-based services for each of Cyren’s email security, web security, antimalware, and advanced threat protection offerings. We sell all of our solutions as subscription services, either to OEMs and service providers or directly or indirectly to enterprises. -25- Cost of Revenue Personnel costs, which consist of salaries, benefits, bonuses, and stock-based compensation for employees that operate our cloud infrastructure and provide support services to our customers, as well as data center costs, are the most significant components of our cost of revenues. Other costs include third-party contractors, royalties for use of third-party technologies, amortization of intangibles, and depreciation of data center equipment. We expect these costs may increase in absolute dollars as we continue to optimize our cloud infrastructure and our support services, but should reduce as a percentage of overall revenue. Operating Expenses Our operating expenses consist of research and development, sales and marketing, and general and administrative expenses. Personnel costs, which consist of salaries, benefits, bonuses, and stock-based compensation, are the most significant component of our operating expenses. Operating expenses also include allocated overhead costs for facilities, IT, and depreciation. We expect operating expenses to increase in absolute dollars as we continue to grow. Research and Development. Research and development expenses consist primarily of personnel costs and outsourced engineering services. We believe these investments are crucial for our ability to continue to enhance the functionality of our services, as well as to develop and introduce new services to the market. Development costs related to internal use technology that supports our security services are capitalized on the balance sheet, while other development costs are expensed as they are incurred. Sales and Marketing. Sales and marketing expenses primarily include personnel costs, sales commissions, marketing activities, and travel associated with sales and marketing. We market and sell our services worldwide through our sales organization and distribution channels. We capitalize sales commissions paid to internal sales personnel and amortize these expenses over an estimated period of benefit that reflects the expected future revenue streams. We reduced sales and marketing expenses in 2020 but anticipate that we may need to increase investment in these areas related to products newly launched in 2020 and enhance our sales and marketing efforts to support further growth. Sales personnel are typically not immediately productive, and therefore the increase in expenses we incur when adding personnel is not immediately accompanied by increased revenue and in some cases may not result in increased revenue if these new sales personnel are unsuccessful in becoming productive. General and Administrative. General and administrative expenses consist primarily of personnel costs, audit fees, legal expenses, recruiting expenses, and other general operating costs. We expect our general and administrative expenses to grow in absolute dollars as we continue our operational growth. Other Income (Expense), net Other income (expense), net consists generally of capital gain or loss from the sale of assets. Financial Expenses, net Financial expenses, net consist mainly of foreign exchange gains and losses, interest expense on our outstanding debt, and interest income earned on our cash and cash equivalents. In 2020 and 2021, these expenses also included income related to the accounting for a multi-year arrangement where a customer paid upfront the full contract value. This has been deemed a significant financing component under ASC 606. Tax Benefit Our tax benefit is derived primarily from income taxes in foreign jurisdictions in which we conduct business. We estimate income taxes in each of the jurisdictions in which we operate. This process involves determining income tax expense together with calculating the deferred income tax expense related to temporary differences resulting from the differing treatment of items for tax and accounting purposes. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. These temporary differences result in deferred tax assets and liabilities, which are included net as applicable within our balance sheets. For most of our recent years, we have incurred operating losses in Israel and the U.S., where we have recorded a full valuation allowance against our deferred tax assets in those jurisdictions. -26- RESULTS OF OPERATIONS The following table sets forth financial data for the three and nine months ended September 30, 2021 and 2020. Percentages may not add due to rounding. Three months ended Nine months ended September 30 September 30 2021 % 2020 % 2021 % 2020 % Unaudited Unaudited Unaudited Unaudited Revenues $ 7,461 100 % $ 9,114 100 % $ 23,827 100 % $ 27,944 100 % Cost of revenues 3,732 50 % 3,792 42 % 11,332 48 % 11,168 40 % Gross profit 3,729 50 % 5,322 58 % 12,495 52 % 16,776 60 % Operating expenses: Research and development, net 4,100 55 % 4,769 52 % 12,460 52 % 12,264 44 % Sales and marketing 2,785 37 % 2,942 32 % 8,154 34 % 9,123 33 % General and administrative 2,336 31 % 2,302 25 % 6,801 29 % 6,992 25 % Total operating expenses 9,221 124 % 10,013 110 % 27,415 115 % 28,379 102 % Operating loss (5,492 ) (74 )% (4,691 ) (51 )% (14,920 ) (63 )% (11,603 ) (42 )% Other income (expense), net 5 0 % 1 0 % (12 ) 0 % 9 0 % Financial expense, net (320 ) (4 )% (235 ) (3 )% (821 ) (3 )% (757 ) (3 )% Loss before taxes (5,807 ) (78 )% (4,925 ) (54 )% (15,753 ) (66 )% (12,351 ) (44 )% Tax benefit 20 0 % 33 0 % 181 1 % 94 0 % Net loss $ (5,787 ) (78 )% $ 4,892 (54 )% $ (15,572 ) (65 )% $ (12,257 ) (44 )% -27- Three and Nine months Ended September 30, 2021 Compared to the Three and Nine months Ended September 30, 2020 Revenues. Revenues for the three and nine months ended September 30, 2021 decreased $1.7 million, or 18%, and $4.1 million or 15%, respectively, as compared to the corresponding periods last year. The decrease was mainly driven by a contract reduction from our largest customer (as first disclosed in the Q3 2020 Form 10-Q), which was effective in Q2 2021 and is detailed in Note 6.b. The revenue impact of this contract reduction was $0.7 million and $1.7 million for the three and nine months ended September 30, 2021, respectively. Customer renewals at lower values and churn, coupled with the end of life of several legacy Enterprise products during 2020 also contributed to the decline in revenue for the respective periods. During the second quarter of 2020, the Company released two new products, Cyren Inbox Security and Threat InDepth. Since these product launches, the Company has signed numerous new customer contracts representing over $2.5 million in revenue, but due to the timing and ratable nature of the contracts, there was not a material amount of revenue recognized in the nine months of 2021. Cost of Revenues. Cost of revenues for the three months ended September 30, 2021 were consistent with the corresponding period last year. Cost of revenue for the nine months ended September 30, 2021 increased by $0.2 million or 1% as compared to the corresponding periods last year. For the three months ended September 30, 2021, cost of revenues represented 50% of revenue, compared to 42% during the prior year, and accordingly, gross margins for the period were 50% for the three months ended September 30, 2021 compared to 58% for the same period in the prior year. For the nine months ended September 30, 2021 cost of revenues represented 48% of revenue, compared to 40% during the prior year, and accordingly, gross margins for the period were 52% for the nine months ended September 30, 2021 compared to 60% for the same period in the prior year. The increase on a year-to-date basis is driven by an increase in amortization of capitalized development expenses of $0.3 million as a result of the newest Enterprise products launched in Q2 2020, an increase in bonus and stock-based compensation expense of $0.2 million and $0.1 million in the use of consultants. Offsetting the overall increase was a decrease in payroll and related costs of approximately $0.1 million due to a decline employee headcount of 32 employees as of September 30, 2021 compared to 35 as of September 30, 2020. Additional decreases were related to $0.2 million in costs associated with our global network and data centers as well as depreciation associated with data center assets and $0.1 million associated with royalties due to the decline in revenue. Operating Expenses. Total operating expenses for the three and nine months ended September 30, 2021 decreased $0.8 million, or 8%, and $1.0 million or 3%, respectively, as compared to the corresponding periods last year. Operating expenses for the three months ended September 30, 2021, represented 124% of revenue, compared to 110% for the three months ended September 30, 2020. For the nine months ended September 30, 2021, operating expenses represented 115% of revenue, compared to 102% for the nine months ended September 30, 2020. The decrease in operating expenses was primarily due to a decrease in employee headcount, which totaled 171 employees at the end of September 30, 2021, compared to 191 employees at the end of September 30, 2020. -28- Research and Development, Net. Research and development expenses, net decreased $0.7 million, or 14% for the three months ended September 30, 2021. For the nine months ended September 30, 2021, research and development expenses, net increased by $0.2 million or 2% as compared to the corresponding period last year. R&D expense, net for the three months ended September 30, 2021 represented 55% of revenue, compared to 52% a year ago. For the nine months ended September 30, 2021, R&D expense, net represented 52% of revenue compared to 44% a year ago. R&D headcount was 111 employees as of September 30, 2021 compared to 118 as of September 30, 2020. Capitalization of technology development, which reduces expenses, decreased to zero for the three months ended September 30, 2021 from $0.2 million for the three months ended September 30, 2020 primarily driven by the new product launch in the second quarter of 2020 which as a result, in subsequent quarters, the capitalization has declined, leading to higher R&D costs. This was offset by the one-time write-off of $0.7 million in Q3 2020 of a previously capitalized R&D project that did not reoccur in Q3 2021. The decrease in R&D expense, net is also driven by reduced employee headcount leading to lower payroll and related costs of $0.2 million. Capitalization of technology development, which reduces expenses, decreased to $0.2 million for the nine months ended September 30, 2021 from $1.8 million for the nine months ended September 30, 2020 primarily driven by the new product launch in the second quarter of 2020 which as a result, in subsequent quarters, the capitalization has declined, leading to higher R&D costs. This was offset by the one-time write-off of $0.7 million in Q3 2020 of a previously capitalized R&D project that did not reoccur in Q3 2021. The decrease in R&D expense, net is also driven by reduced employee headcount leading to lower payroll and related costs of $0.5 million and a decrease in the use of outside services and consultants of $0.2 million. Sales and Marketing. Sales and marketing expenses decreased $0.2 million, or 5% for the three months ended September 30, 2021 and decreased by $1.0 million, or 11%, for the nine months ended September 30, 2021, as compared to the corresponding periods last year. Sales and marketing expenses for the three months ended September 30, 2021 represented 37% of revenue, compared to 32% a year ago. For the nine months ended September 30, 2021, sales and marketing expenses represented 34% of revenue compared to 33% a year ago. For the three months ended September 30, 2021 compared to the same period a year ago, the decrease in sales and marketing expense was due to a reduction of overall sales and marketing headcount to 33 employees at the end of the third quarter of 2021 compared to 41 employees at the end of the third quarter of 2020. The primary driver of the decline is due to payroll and related costs decreasing by $0.1 million as a result of the decrease in headcount. For the nine months ended September 30, 2021 compared to the same period a year ago, the decrease in sales and marketing expense was due to a reduction of overall sales and marketing headcount to 33 employees at the end of the third quarter of 2021 compared to 41 employees at the end of the third quarter of 2020. Payroll and payroll-related costs decreased by $0.7 million, intangible asset amortization decreased by $0.1 million as an asset had been fully amortized in Q3 2020, travel and related costs decreased by $0.1 million, and allocated costs to sales and marketing decreased by $0.2 million due the decline in headcount. These decreases were offset by an increase in the use of outside services by $0.1 million to enhance our sales and marketing efforts to support the growth of our 2020 new product releases. General and Administrative. General and administrative (G&A) expenses for the three months ended September 30, 2021 were consistent with the corresponding periods last year. For the nine months ended September 30, 2021, G&A expenses decreased by $0.2 million, or 3%, as compared to the corresponding periods last year. G&A expenses for the three months ended September 30, 2021 represented 31% of revenue, compared to 25% a year ago. G&A expense for the nine months ended September 30, 2021 represented 29% of revenue, compared to 25% a year ago. For the nine months ended September 30, 2021 compared to the same period a year ago, legal expenses increased by $0.3 million primarily due to additional legal work related to two capital raises in 2021 compared to only one in 2020. This increase was offset by a decrease in travel-related costs of $0.1 million due to COVID-19, a decrease in bad debt expense of $0.2 million due to improved customer collections, a $0.1 million decrease in Corporate & IT allocations due to the decline in headcount and a $0.1 million decrease due to the reduction in the use of certain outside services and consultants. -29- Other Income (Expense), Net. Other income, net for the three months ended September 30, 2021 was $0.005 million primarily related to a miscellaneous cash receipt. Other income, net for the three months ended September 30, 2020 was $0.001 million with $0.001 million related to the proceeds on the disposal of fixed assets. Other income, net for the nine months ended September 30, 2021 was an expense of $0.012 million primarily related to the disposal of fixed assets associated with the exit of an office lease of $0.017 million offset by a miscellaneous cash receipt of $0.005 million. Other income, net for the nine months ended September 30, 2020 was $0.009 million with $0.013 million of expense associated with the disposal of fixed assets associated with the exit of an office lease offset by income of $0.021 million related to miscellaneous cash receipts. Financial Expense, Net. Financial expenses, net, were consistent for the three months ended September 30, 2021 as compared to the corresponding periods last year. For the nine months ended September 30, 2021, financial expenses, net decreased by $0.06 million or 8%, as compared to the corresponding periods last year. For the nine months ended September 30, 2021, interest expenses increased by $0.06 million due to a full quarter of interest expense for the three months ended March 31, 2021 due to the issuance of the Convertible Debentures on March 19, 2020 which resulted in a partial period of interest expense in the first quarter of 2020. Effective Corporate Tax Rates Corporate tax rates and real capital gains tax in Israel were 23% for the three months ended September 30, 2021 and 2020. Our German subsidiary is subject to German tax at a consolidated rate of approximately 30%. Other non-Israeli subsidiaries are taxed according to the tax laws in their respective countries of residence. We do not provide deferred tax liabilities when we intend to reinvest earnings of foreign subsidiaries indefinitely. As of September 30, 2021, there are no undistributed earnings of foreign subsidiaries. We may currently qualify as an “industrial company” within the definition of the Law for the Encouragement of Industry (Taxation) and, as such, we may be eligible for certain tax benefits, including, inter alia, special depreciation rates for machinery, equipment and buildings, amortization of patents, certain other intangible property rights and deduction of share issuance expenses. -30- Net Operating Loss Carry-Forwards As of December 31, 2020, Cyren Ltd.’s net operating loss carryforwards for tax purposes amounted to $102.0 million and capital loss carryforwards of $17.8 million which may be carried forward and offset against taxable income in the future, for an indefinite period. As of December 31, 2020, the U.S. subsidiary had net operating loss carryforwards of $40.7 million for federal tax purposes and $10.6 million for state tax purposes. These losses may offset any future U.S. taxable income of the U.S. subsidiary and will expire in the years 2021 through 2040. Management currently believes that based upon its estimations for future taxable income, it is more likely than not that the deferred tax assets regarding the loss carryforwards will not be utilized in the foreseeable future. Thus, a valuation allowance was provided to reduce deferred tax assets to their realizable value. LIQUIDITY AND CAPITAL RESOURCES The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future and therefore, the Company intends to finance operating costs over the next twelve months through a combination of existing cash on hand, reducing operating spend, potentially divesting non-core assets, and future issuances of equity and/or debt securities. As of September 30, 2021, we had an accumulated deficit of $264.2 million, cash and cash equivalents of $17.9 million, and generated a year-to-date net loss of $15.6 million. We have incurred losses since inception and expect to continue to incur losses for the foreseeable future. Current assets amounted to approximately $24.3 million with current liabilities of approximately $25.3 million, resulting in negative working capital (defined as current assets minus current liabilities) of approximately $1.0 million. The current cash balance and historical trend of cash used in operations along with the maturity of the convertible notes in December 2021, lack of certainty regarding a future capital raise and our ability to renegotiate the term of the convertible notes, raise substantial doubt about our ability to continue as a going concern for the next twelve months from the date of issuance of this Form 10-Q. As the convertible notes mature in December 2021, the Company is currently negotiating to restructure the convertible notes with the noteholders and at this time is uncertain as to the outcome. If the restructuring discussions are not successful, the Company intends to use its available cash resources to repay the principal upon maturity per the terms of the convertible notes. The inability to borrow or raise sufficient funds on commercially reasonable terms, would have serious consequences to our financial condition and results of operations. Our future capital requirements will depend on many factors, including, but not limited to our growth, market acceptance of our offerings, the timing and extent of spending to support our efforts to develop our platform, and the expansion of sales and marketing activities. We may be required to seek additional equity or debt financing. If additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we issue additional equity securities to raise additional funds, further dilution to existing stockholders may occur. However, we cannot predict with certainty the outcome of our actions to generate liquidity, including the availability of additional financing. If we are unable to raise additional capital when desired, our business, financial condition, and results of operations could be adversely affected. Please see the Financingssection below for more details on the Company’s recent efforts to fund operating activities. Outlook On July 8, 2021, the shareholders of the Company approved an increase in the number of authorized ordinary shares from 110,000,000 ordinary shares of nominal value NIS 0.15 per share to 160,000,000 ordinary shares of nominal value NIS 0.15 per share. The Company’s ability to continue as a going concern is dependent upon the Company growing the business, obtaining the necessary financing to meet its obligations, repay its liabilities arising from normal business operations, and the Company’s ability to gain compliance with the Nasdaq Capital Market listing standards (see Item 1A Risk Factors in the 2020Annual Report and Item 1A. Risk Factors in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 for additional information). The initial cure period ended on October 5, 2021. The Company received a 180-day extension in October 2021 to meet the minimum bid price requirement. The Company now has until April 4, 2022 to meet this requirement. The Company will continue to monitor the bid price for its ordinary shares and consider various options available to it if the ordinary shares do not trade at a level that is likely to regain compliance. These options include effecting a reverse stock split. There can be no assurance that the Company will regain compliance with the minimum bid price requirement or maintain compliance with any of the other Nasdaq continued listing requirements. The Company is currently negotiating to restructure the convertible notes with the noteholders and at this time is uncertain as to the outcome. The Company’s ability to raise additional equity is limited by the number of authorized shares available. While the Company intends to finance operating costs over the next twelve months through a combination of existing cash on hand, reducing operating spend, potentially divesting non-core assets, amending the terms of outstanding debt securities, and future issuances of equity and/or debt securities the Company cannot predict the availability of additional financing or the outcome of its actions to generate liquidity or regain compliance with the Nasdaq Capital Market listing standards. Over the past several years, the Company has devoted most of its effort to research and development and increasing revenues through additional investments in sales and marketing. The Company generated a net loss of $15.6 million for the nine months ended September 30, 2021 and a negative cash flow of $12.5 million from operating activities for the nine months ended September 30, 2021. The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. -31- Cash Flows from Operating Activities Cash used in operating activities was $12.5 million for the nine months ended September 30, 2021 as compared to $5.4 million for the nine months ended September 30, 2020. For the nine months ended September 30, 2021, the primary factors affecting our operating cash flows during the period were our net loss of $15.6 million, adjusted for non-cash items of $1.8 million of stock-based compensation expense, $1.3 million for amortization of our non-cash operating lease expense, $3.9 million for depreciation and amortization of our property, equipment, and intangible assets, $1.0 million for amortization of deferred commissions and $1.0 million associated with interest and amortization of debt issuance costs associated with our convertible notes and debentures. The primary drivers of the changes in operating assets and liabilities were a $1.5 million decrease in operating lease liabilities, a $0.8 million decrease in capitalization of deferred commissions, a $0.7 million decrease in prepaid expenses and other receivables, and offset by an increase in trade receivables of $2.9 million primarily driven by a delayed payment from a customer of $2.1 million which was received in October 2021. For the nine months ended September 30, 2020, the factors affecting our operating cash flows during the period were our net loss of 12.3 million, adjusted for non-cash items of $1.9 million of stock-based compensation expense, $1.5 million for amortization of our operating lease right-of-use assets, $3.9 million for depreciation and amortization of our property, equipment and intangible assets, and $1.2 million for amortization of deferred commissions. The primary drivers of the changes in operating assets and liabilities were an increase of $1.0 million in deferred revenue offset by a $1.5 million decrease in operating lease liabilities and a $0.9 million decrease in capitalization of deferred commissions. Cash Flows from Investing Activities For the nine months ended September 30, 2021, net cash used in investing activities was $0.7 million which primarily consisted of $0.2 million for capitalization of technology and $0.5 million used to purchase property and equipment. For the nine months ended September 30, 2020, net cash used in investing activities was $2.6 million which primarily consisted of $1.1 million for capitalization of technology and $1.5 million used to purchase property and equipment. Our capital expenditures over the past three years has consisted primarily of continued investment in R&D and purchases of property and equipment to modernize and expand our data centers and to invest in our infrastructure to support new products and to facilitate the growth of the Company. Capitalization of technology has decreased in 2021 compared to 2020 primarily due to the new products launched in the first half of 2020. Cash Flows from Financing Activities For the nine months ended September 30, 2021, net cash generated by financing activities was $21.9 million as we issued to several institutional investors in February 2021 in a registered direct offering (the “Offering”) 12,000,000 of our ordinary shares at a purchase price of $1.15 per share for net proceeds of approximately $12.6 million. In September 2021, we issued 14,152,779 ordinary shares to certain institutional investors at a purchase from of $0.72 per share for net proceeds of approximately $9.3 million. For the nine months ended September 30, 2020, net cash generated by financing activities was $9.4 million which was attributable to the Convertible Debentures issued on March 19, 2020 with gross proceeds of $10.2 million, offset by the payment of debt issuance costs of $0.8 million. Working Capital As of September 30, 2021, we had negative working capital of $1.0 million and as of September 30, 2020, we had positive working capital of $0.4 million. The decrease in working capital in 2021 compared to 2020 was driven by the $10.0 million convertible notes which are due December 2021 and as a result, are presented in current liabilities as of September 30, 2021, compared to long-term liabilities as of September 30, 2020 and offset by a higher cash balance as of September 30, 2021 compared to September 30, 2020 due to the capital raise noted above in September 2021. -32- Financings On December 5, 2018, the Company issued $10.0 million aggregate principal amount of convertible notes in a private placement to affiliates of an existing minority institutional shareholder. The convertible notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes have a 3-year term and mature in December 2021, unless converted in accordance with their terms prior to maturity. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. We are currently negotiating to restructure the convertible notes with the noteholders to postpone the final repayment date by several months under certain terms, although there is no assurance that we will be able to do so on commercially reasonable terms or at all. If the restructuring discussions are not successful, the Company intends to use its available cash resources to repay the principal upon maturity per the terms of the convertible notes. On November 7, 2019, we completed a rights offering that raised gross proceeds of $8.0 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. In addition, the convertible notes are subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price). On March 19, 2020, we issued $10.25 million aggregate principal amount of Convertible Debentures in a private placement to certain investors. The Convertible Debentures are secured by a guarantee by two of our subsidiaries and carry a 5.75% interest rate, payable semi-annually in cash or, subject to the satisfaction of certain equity conditions, in ordinary shares. The Convertible Debentures mature in March 2024, unless converted in accordance with their terms prior to maturity. The Convertible Debentures have an initial conversion price of $0.75 per share, subject to adjustments. If the closing bid price of our ordinary shares has been at least $2.25 (subject to adjustment) for at least 20 trading days during any 30 consecutive trading day period, and certain conditions are satisfied, we may force a conversion of all or any part of the outstanding principal amount of the Convertible Debentures, accrued and unpaid interest and any other amounts then owing, subject to certain conditions. On February 16, 2021, we issued to several institutional investors in a registered direct offering, 12,000,000 of our Ordinary Shares at a purchase price of $1.15 per share for net proceeds of approximately $12.6 million. We intend to use the proceeds from this offering for working capital and general corporate purposes. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.38. We also issued to the placement agent or its designees warrants to purchase up to 720,000 ordinary shares, representing 6% of the aggregate number of ordinary shares sold in the offering. The placement agent warrants have an exercise price equal to $1.4375, or 125% of the offering price, per Ordinary Share and became exercisable on August 16, 2021 for five years from the effective date of the offering. On September 17, 2021, we issued to several institutional investors in a private placement, 14,152,799 of our ordinary shares at a purchase price of $0.72 per share and warrants to purchase up to 14,152,779 ordinary shares at an exercise price of $0.60 per share. The warrants will be exercisable immediately and terminate on March 17, 2025. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.02. We also issued to the placement agent or its designees warrants to purchase up to 849,167 ordinary shares, representing 6.0% of the aggregate number of ordinary shares sold in the offering. The placement agent warrants have an exercise price equal to $0.90 per share, or 125% of the offering price per share and were exercisable immediately and terminate on March 17, 2025. -33- Registration Statements In connection with our private placement to Warburg Pincus in November 2017, in which we issued approximately 10.6 million ordinary shares for $1.85 per share, we and Warburg Pincus entered into a registration rights agreement, which, among other things, provides Warburg Pincus with three demand registration rights, piggyback and shelf registration rights. The demand registration rights became exercisable as of August 6, 2018, subject to certain customary blackout periods. In connection with the issuance of the Convertible Debentures, we entered into a registration rights agreement with the purchasers. Pursuant to that agreement, we filed a registration statement on Form S-3 with the SEC covering the resale of our ordinary shares that are issuable to the purchasers upon any conversion of the Convertible Debentures or as interest payments. On September 21, 2018, we filed a shelf registration statement on Form F-3 with the SEC, which we converted to a Form S-3 on August 16, 2019. This registration statement enables us to issue debt securities, ordinary shares, warrants, or subscription rights up to an aggregate amount of $50 million. Under the rules governing shelf registration statements, we will file a prospectus supplement with the SEC which describes the amount and type of securities being offered each time we issue securities under this registration statement. No securities were issued under the registration statement on Form F-3. In November 2019, we issued shares as part of our rights offerings, and in February 2021, we issued shares in the registered direct offering using our Form S-3 as described above. On October 1, 2021, as a part of the private placement noted above in September 2021, we a filed shelf registration statement on Form S-3 with the SEC. This registration registered 29,154,725 ordinary shares, consisting of (i) 14,152,779 ordinary shares, (ii) 14,152,779 ordinary shares issuable upon the exercise of warrants issued in a private placement described above, and (iii) 849,167 ordinary shares issuable upon exercise of the placement agent warrants issued in a private placement described above. Off-Balance Sheet Arrangements As of September 30, 2021, we did not have any off-balance sheet arrangements. Critical Accounting Policies and Estimates Our significant accounting policies are discussed in Note 2. Significant Accounting Policies to our consolidated financial statements included in the Company’s 2020 Annual Report. There have been no significant changes to these policies for the three months ended September 30, 2021, except as described in Note 2. Significant Accounting Policies to our condensed consolidated financial statements are included elsewhere in this Quarterly Report. The critical accounting policies requiring estimates, assumptions, and judgments that we believe have the most significant impact on our consolidated financial statements are described in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2020 Annual Report. Recent Accounting Pronouncements Please refer to Note 2. Significant Accounting Policies to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a full description of recent accounting pronouncements. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Not required for smaller reporting companies. Special Note Regarding Forward-Looking Statements This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements concern expectations, beliefs, projections, plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts. We urge you to consider that statements which use the terms “anticipate,” “believe,” “expect,” “plan,” “intend,” “estimate”, “will” and similar expressions are intended to identify forward-looking statements. Specifically, this Quarterly Report contains forward-looking statements regarding: ? our expectations that our utilization of our cloud infrastructure will increase and provide an opportunity for improved gross margins; ? our expectations regarding our partnership with Microsoft; ? our expectations regarding our future profitability and revenue growth; ? our expectations that R&D expenses may increase as we enhance newly released products from 2020; ? our beliefs regarding the importance of R&D; ? our expectation to lower R&D investment as a percentage of revenue in the future and to drive more revenue from existing solutions rather than by adding new solutions; -34- ? our expectations regarding reducing the historical rate of headcount growth and its resulting impact on our gross and operating margins over time; ? our expectations regarding growth of our enterprise business and its expected impact on our business, including its contribution to our cash flow and return on investment; ? our expectations regarding our capital expenditures for 2021; ? our belief regarding the adequacy of our existing capital resources and other future measures to satisfy our expected liquidity requirements; ? our expectations regarding trends in the market for internet security and technology industry; and ? our expectations regarding existing and new threats, key challenges and opportunities in our industry, and their impact on our business, including the impact of innovations in the technology industry. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties, and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. The most important factors that could prevent us from achieving our goals, and cause the assumptions underlying forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward-looking statements include, but are not limited to, the following: ? our ability to continue as a going concern; ? our ability to restructure or refinance our convertible notes; ? our ability to execute our business strategies, including our sales and business development plan; ? our ability to timely and successfully enhance and improve our existing solutions and introduce our new solutions; ? the commercial success of such enhancements and new solutions; ? lack of demand for our solutions, including as a result of actual or perceived decreases in levels of advanced cyber attacks; ? our ability to manage our cost structure, avoid unanticipated liabilities and achieve profitability; ? our ability to grow our revenues, including the ability of existing solutions to drive sufficient revenue; ? our ability to attract new customers and increase revenue from existing customers; ? market acceptance of our existing and new product offerings; ? the success of our partnership with Microsoft; ? our ability to adapt to changing technological requirements and shifting preferences of our customers and their users; ? the impact of the COVID-19 outbreak; ? our continued listing on Nasdaq; -35- ? loss of any of our large customers; ? adverse conditions in the national and global financial markets; ? the impact of currency fluctuations; ? political and other conditions in Israel, Germany, and Iceland that may limit our R&D activities; ? increased competition or our ability to anticipate or effectively react to competitive challenges; ? the ability of our brand development strategies to enhance our brand awareness; ? our ability to retain key personnel; ? performance of our OEM partners, service providers, and resellers; ? our ability to successfully estimate the impact of regulatory and litigation matters; ? our ability to comply with applicable laws and regulations and the impact of changes in applicable laws and regulations, including tax legislation or policies; ? economic, regulatory, and political risks associated with our international operations; ? the impact of cyber attacks or a security breach of our systems; ? our ability to protect our brand name and intellectual property rights; ? the impact of our controlling shareholder’s decisions, which may differ with respect to our strategic direction; and ? our ability to successfully estimate the impact of certain accounting and tax matters, including the effect on our company of adopting certain accounting pronouncements. -36- The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. In addition, you should consult other disclosures made by the Company (such as in our other filings with the SEC or in company press releases) for other factors that may cause actual results to differ materially from those projected by the Company. Please refer to the factors described in Part II. Item 1A. Risk Factors in the Quarterly Report for the quarterly period ended March 31, 2021 and Part I. Item 1A. Risk Factors, of the 2020 Annual Report for additional information regarding factors that could affect our results of operations, financial condition, and liquidity. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances, or otherwise after the date hereof. Impact from the COVID-19 Outbreak On March 11, 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new coronavirus as a “pandemic” which is now known as COVID-19. The outbreak has impacted thousands of individuals worldwide. In response, many countries have implemented measures to combat the outbreak which have impacted global business operations. As of the date of issuance of the financial statements, the Company’s operations have not been significantly impacted, however, the Company continues to monitor the situation. The ultimate extent of the impact of any epidemic, pandemic, or other health crisis on our business, financial condition, and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic or other health crisis and actions taken to contain or prevent their further spread, among others. No impairments were recorded as of the balance sheet date as no triggering events or changes in circumstances had occurred as of quarter-end; however, due to significant uncertainty surrounding the situation, management’s judgment regarding this could change in the future. In addition, while the Company’s results of operations, cash flows and financial condition could be negatively impacted, the extent of the impact cannot be reasonably estimated at this time. ITEM 4. CONTROLS AND PROCEDURES Management’s Evaluation of Disclosure Controls and Procedures In order to ensure that the information we must disclose in our filings with the SEC is recorded, processed, summarized, and reported on a timely basis, we have formalized our disclosure controls and procedures. Our principal executive officer and principal financial officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures, as defined in Securities and Exchange Act Rules 13a-15(e) and 15d-15(e) as of September 30, 2021. Based on such evaluation, such officers have concluded that, as of September 30, 2021, our disclosure controls and procedures were effective. Changes in Internal Control over Financial Reporting There were no changes to our internal control over financial reporting, as defined in Securities and Exchange Act Rules 13a-15(f) and 15d-15(f), that occurred during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. -37- PART II – OTHER INFORMATION. ITEM 6. EXHIBITS Exhibit No. Description of Exhibits 4.2 Amended and Restated Articles of Association, as amended on September 9, 2021 (incorporated by reference to Exhibit 4.2 to the Form S-3 (File No. 333-259959) filed on October 1, 2021. 31.1 Certification by Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification by Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification by Chief Executive Officer and Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File – the cover page iXBRL tags are embedded within the Inline XBRL document. -38- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYREN LTD. November 15, 2021 /s/ Brett Jackson Brett Jackson Chief Executive Officer (Duly Authorized Officer) November 15, 2021 /s/ Kenneth Tarpey Kenneth Tarpey Chief Financial Officer (Principal Financial Officer) -39- 00-0000000 false --12-31 Q3 0001084577 0001084577 2021-01-01 2021-09-30 0001084577 2021-10-31 0001084577 2021-09-30 0001084577 2020-12-31 0001084577 2021-07-01 2021-09-30 0001084577 2020-07-01 2020-09-30 0001084577 2020-01-01 2020-09-30 0001084577 us-gaap:CommonStockMember 2020-06-30 0001084577 cyrn:ShareCapitalMember 2020-06-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2020-06-30 0001084577 2020-06-30 0001084577 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001084577 cyrn:ShareCapitalMember 2020-07-01 2020-09-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-07-01 2020-09-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2020-07-01 2020-09-30 0001084577 us-gaap:CommonStockMember 2020-09-30 0001084577 cyrn:ShareCapitalMember 2020-09-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-09-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2020-09-30 0001084577 2020-09-30 0001084577 us-gaap:CommonStockMember 2019-12-31 0001084577 cyrn:ShareCapitalMember 2019-12-31 0001084577 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2019-12-31 0001084577 2019-12-31 0001084577 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001084577 cyrn:ShareCapitalMember 2020-01-01 2020-09-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-09-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2020-01-01 2020-09-30 0001084577 us-gaap:CommonStockMember 2021-06-30 0001084577 cyrn:ShareCapitalMember 2021-06-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2021-06-30 0001084577 2021-06-30 0001084577 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001084577 cyrn:ShareCapitalMember 2021-07-01 2021-09-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-01 2021-09-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2021-07-01 2021-09-30 0001084577 us-gaap:CommonStockMember 2021-09-30 0001084577 cyrn:ShareCapitalMember 2021-09-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-09-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2021-09-30 0001084577 us-gaap:CommonStockMember 2020-12-31 0001084577 cyrn:ShareCapitalMember 2020-12-31 0001084577 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2020-12-31 0001084577 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001084577 cyrn:ShareCapitalMember 2021-01-01 2021-09-30 0001084577 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001084577 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-09-30 0001084577 us-gaap:RetainedEarningsUnappropriatedMember 2021-01-01 2021-09-30 0001084577 2021-02-11 0001084577 2021-09-01 2021-09-15 0001084577 2021-09-15 0001084577 2020-01-01 2020-12-31 0001084577 us-gaap:DebtMember 2019-12-01 2019-12-31 0001084577 2019-12-01 2019-12-31 0001084577 2021-07-01 2021-07-08 0001084577 2018-12-05 0001084577 2018-11-05 2018-12-05 0001084577 2019-10-05 2019-11-07 0001084577 2019-11-07 0001084577 2021-02-16 0001084577 2021-02-01 2021-02-16 0001084577 us-gaap:PrivatePlacementMember 2021-09-01 2021-09-17 0001084577 us-gaap:PrivatePlacementMember 2021-09-17 0001084577 us-gaap:WarrantMember 2021-09-01 2021-09-19 0001084577 us-gaap:WarrantMember 2021-09-19 0001084577 2021-09-19 0001084577 cyrn:IssuanceOfConvertibleNotesMember 2021-09-30 0001084577 us-gaap:ConvertibleNotesPayableMember 2020-03-31 0001084577 cyrn:ConvertibleDebenturesMember 2020-03-31 0001084577 2020-03-01 2020-03-31 0001084577 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-09-30 0001084577 cyrn:ConvertibleDebenturesMember 2021-09-30 0001084577 cyrn:ConvertibleDebenturesMember 2021-01-01 2021-09-30 0001084577 us-gaap:ConvertibleNotesPayableMember 2021-09-30 0001084577 cyrn:IssuanceOfConvertibleDebenturesMember 2021-03-01 2021-03-31 0001084577 cyrn:IssuanceOfConvertibleDebenturesMember 2021-09-01 2021-09-30 0001084577 2020-07-11 0001084577 2020-07-01 2020-07-11 0001084577 cyrn:IssuanceOfConvertibleDebenturesMember 2020-09-30 0001084577 2019-07-30 0001084577 cyrn:NonEmployeePlanMember 2019-07-30 0001084577 cyrn:NonEmployeePlanMember 2021-09-30 0001084577 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001084577 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001084577 cyrn:EmployeesAndDirectorsStockOptionMember 2020-12-31 0001084577 cyrn:EmployeesAndDirectorsStockOptionMember 2021-01-01 2021-09-30 0001084577 cyrn:EmployeesAndDirectorsStockOptionMember 2021-09-30 0001084577 cyrn:RangeOneMember 2021-09-30 0001084577 cyrn:RangeOneMember 2021-01-01 2021-09-30 0001084577 cyrn:RangeTwoMember 2021-09-30 0001084577 cyrn:RangeTwoMember 2021-01-01 2021-09-30 0001084577 cyrn:RangeThreeMember 2021-09-30 0001084577 cyrn:RangeThreeMember 2021-01-01 2021-09-30 0001084577 cyrn:RangeFourMember 2021-09-30 0001084577 cyrn:RangeFourMember 2021-01-01 2021-09-30 0001084577 cyrn:RangeFiveMember 2021-09-30 0001084577 cyrn:RangeFiveMember 2021-01-01 2021-09-30 0001084577 cyrn:ExercisePriceRangeMember 2021-09-30 0001084577 cyrn:ExercisePriceRangeMember 2021-01-01 2021-09-30 0001084577 cyrn:IssuanceDateThreeMember 2021-06-30 0001084577 cyrn:IssuanceDateThreeMember 2021-01-01 2021-06-30 0001084577 cyrn:IssuanceDateFourMember 2021-06-30 0001084577 cyrn:IssuanceDateFourMember 2021-01-01 2021-06-30 0001084577 cyrn:IssuanceDateFivesMember 2021-06-30 0001084577 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001084577 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0001084577 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0001084577 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0001084577 us-gaap:CostOfSalesMember 2020-01-01 2020-09-01 0001084577 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001084577 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001084577 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001084577 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-01 0001084577 us-gaap:SellingAndMarketingExpenseMember 2021-07-01 2021-09-30 0001084577 us-gaap:SellingAndMarketingExpenseMember 2020-07-01 2020-09-30 0001084577 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-09-30 0001084577 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-09-01 0001084577 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001084577 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001084577 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001084577 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-01 0001084577 2020-01-01 2020-09-01 0001084577 country:US 2021-07-01 2021-09-30 0001084577 country:US 2020-07-01 2020-09-30 0001084577 country:US 2021-01-01 2021-09-30 0001084577 country:US 2020-01-01 2020-09-30 0001084577 country:DE 2021-07-01 2021-09-30 0001084577 country:DE 2020-07-01 2020-09-30 0001084577 country:DE 2021-01-01 2021-09-30 0001084577 country:DE 2020-01-01 2020-09-30 0001084577 srt:EuropeMember 2021-07-01 2021-09-30 0001084577 srt:EuropeMember 2020-07-01 2020-09-30 0001084577 srt:EuropeMember 2021-01-01 2021-09-30 0001084577 srt:EuropeMember 2020-01-01 2020-09-30 0001084577 srt:AsiaPacificMember 2021-07-01 2021-09-30 0001084577 srt:AsiaPacificMember 2020-07-01 2020-09-30 0001084577 srt:AsiaPacificMember 2021-01-01 2021-09-30 0001084577 srt:AsiaPacificMember 2020-01-01 2020-09-30 0001084577 country:IL 2021-07-01 2021-09-30 0001084577 country:IL 2020-07-01 2020-09-30 0001084577 country:IL 2021-01-01 2021-09-30 0001084577 country:IL 2020-01-01 2020-09-30 0001084577 us-gaap:ReclassificationOtherMember 2021-07-01 2021-09-30 0001084577 us-gaap:ReclassificationOtherMember 2020-07-01 2020-09-30 0001084577 us-gaap:ReclassificationOtherMember 2021-01-01 2021-09-30 0001084577 us-gaap:ReclassificationOtherMember 2020-01-01 2020-09-30 0001084577 cyrn:OEMAndEmbeddedSecurityMember 2021-07-01 2021-09-30 0001084577 cyrn:OEMAndEmbeddedSecurityMember 2020-07-01 2020-09-30 0001084577 cyrn:OEMAndEmbeddedSecurityMember 2021-01-01 2021-09-30 0001084577 cyrn:OEMAndEmbeddedSecurityMember 2020-01-01 2020-09-30 0001084577 cyrn:EnterpriseAndSMBMember 2021-07-01 2021-09-30 0001084577 cyrn:EnterpriseAndSMBMember 2020-07-01 2020-09-30 0001084577 cyrn:EnterpriseAndSMBMember 2021-01-01 2021-09-30 0001084577 cyrn:EnterpriseAndSMBMember 2020-01-01 2020-09-30 0001084577 country:IL 2021-09-30 0001084577 country:IL 2020-12-31 0001084577 country:US 2021-09-30 0001084577 country:US 2020-12-31 0001084577 country:DE 2021-09-30 0001084577 country:DE 2020-12-31 0001084577 cyrn:OtherMember 2021-09-30 0001084577 cyrn:OtherMember 2020-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure EX-31.1 2 f10q0921ex31-1_cyren.htm CERTIFICATION Exhibit 31.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Brett Jackson, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Cyren Ltd. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report. 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: November 15, 2021 By: /s/ Brett Jackson Brett Jackson Chief Executive Officer EX-31.2 3 f10q0921ex31-2_cyren.htm CERTIFICATION Exhibit 31.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kenneth Tarpey, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Cyren Ltd. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report. 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: November 15, 2021 By: /s/ Kenneth Tarpey Kenneth Tarpey Chief Financial Officer EX-32.1 4 f10q0921ex32-1_cyren.htm CERTIFICATION Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Cyren Ltd. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Brett Jackson, Chief Executive Officer, and Kenneth Tarpey, Chief Financial Officer, of the Company, do each certify, pursuant to Section 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge: 1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2. the information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company. Date: November 15, 2021 By: /s/ Brett Jackson Brett Jackson Chief Executive Officer By: /s/ Kenneth Tarpey Kenneth Tarpey Chief Financial Officer